Skip to main content
Physician-scientists at IU School of Medicine conduct ground-breaking liver research to understand primary sclerosing cholangitis.

Primary Sclerosing Cholangitis

Primary sclerosing cholangitis (PSC) is a condition that affects the bile ducts. These ducts carry bile from the liver, where bile is produced, to the gallbladder, where it is stored, and to the small intestine, where it aids in digestion. Primary sclerosing cholangitis occurs because of inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis) and narrowing of the ducts. As a result, bile cannot be released to the gallbladder and small intestine, and it builds up in the liver.

Investigators

Craig Lammert, MS, MD

Associate Professor of Medicine

Eric Orman, MD

Associate Professor of Medicine

Open Research Studies for Primary Sclerosing Cholangitis

Mayo RC2

Enrolling: Yes

Principle Investigator: Craig Lammert, MD

Duration: 1 visit

Patient Population: PSC with at least 6 month biochemical presence of chronic cholangitis, must not have NASH.

Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu

Pliant

Enrolling: No

Principle Investigator: Eric Orman, MD

Duration: 12 week study period

Patient Population: PSC patients without cirrhosis.

Drug(s): PLN-74809 Oral

Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu

View the study on clinicaltrials.gov

Progress PSC

Enrolling: Yes

Principle Investigator: Craig Lammert, MD

Duration: 1 visit.

Patient Population: Patients with PSC with ERCP, MRCP or liver biopsy.

Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu

PSC CALID

Enrolling: Yes

Principle Investigator: Craig Lammert, MD

Duration: 1 visit per year over 20 years

Patient Population: Patient population is PSC/pre-transplant with no history concomitant liver disease.

Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu

Closed Primary Sclerosing Cholangitis Studies

  • Safety, Tolerability, and Efficacy of Cilofexor in Non-cirrhotic Adults with Primary Sclerosing Cholangitis (PRIMIS)

    Enrolling: No

    Principle Investigator: Raj Vuppalanchi, MD

    Duration: P3 - 110 weeks

    Patient Population: Non-cirrhotic large duct PSC

    Drug(s): Oral GS9674 (Cilofexor)

    Clinicaltrials.gov